NCT06754267View on ClinicalTrials.gov

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2027

Conditions
Precursor B-Cell Acute Lymphoblastic Leukemia
Interventions
DRUG

Venetoclax

BCL-2 inhibotor

DRUG

Olverembatinib

Tyrosine kinase inhibitor

DRUG

Predinisone

Glucocorticoids

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER